Scholarlink

<p>The PI3K/AKT/mTOR pathway represents an excellent drug target, given its proven druggability and roles in cancer, immune regulation and genetic disorders. However, although some agents targeting this pathway have gained approval, drug development has faced challenges due to tolerability issues and resistance mechanisms, amongst other obstacles. New pharmacological approaches and improved biological and clinical understanding are now renewing interest and confidence in therapeutically modulating PI3K/AKT/mTOR signalling. This Perspective covers the challenges, lessons learned and new efforts in targeting this pathway.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A renaissance in targeting the PI3K/AKT/mTOR pathway

  • 期刊论文

  • 发表日期：

    2026年3月30日

查看全文
  • Sarah E. Conduit,
  • Neil Vasan,
  • Jennifer R. Brown,
  • Matthew W. D. Perry,
  • Bart Vanhaesebroeck

摘要

The PI3K/AKT/mTOR pathway represents an excellent drug target, given its proven druggability and roles in cancer, immune regulation and genetic disorders. However, although some agents targeting this pathway have gained approval, drug development has faced challenges due to tolerability issues and resistance mechanisms, amongst other obstacles. New pharmacological approaches and improved biological and clinical understanding are now renewing interest and confidence in therapeutically modulating PI3K/AKT/mTOR signalling. This Perspective covers the challenges, lessons learned and new efforts in targeting this pathway.